Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
- DOI
- 10.1016/s2213-8587(26)00126-9
- Published
- 2026-08
- Container
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-26-00126-9,
title = {Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study},
author = {Vanita R Aroda and Raffaella Buzzetti and Stine-Mathilde Dalskov and Akshay B Jain and Jonas Hughes Larsen and Chantal Mathieu and Richard E Pratley and Alex Videmark and Torquil Watt and John B Buse},
year = {2026},
journal = {The Lancet Diabetes \& Endocrinology},
doi = {10.1016/s2213-8587(26)00126-9},
url = {https://doi.org/10.1016/s2213-8587(26)00126-9}
}RIS
TY - JOUR TI - Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study AU - Vanita R Aroda AU - Raffaella Buzzetti AU - Stine-Mathilde Dalskov AU - Akshay B Jain AU - Jonas Hughes Larsen AU - Chantal Mathieu AU - Richard E Pratley AU - Alex Videmark AU - Torquil Watt AU - John B Buse PY - 2026 JO - The Lancet Diabetes & Endocrinology DO - 10.1016/s2213-8587(26)00126-9 UR - https://doi.org/10.1016/s2213-8587(26)00126-9 ER -
APA
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. H., Mathieu, C., Pratley, R. E., Videmark, A., Watt, T., & Buse, J. B. (2026). Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(26)00126-9
Source records
- crossref · retrieved 2026-09-27T01:35:08.930Z